Back to News
Market Impact: 0.2
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
Source: globenewswire.com
Healthcare & Biotech
A new dose-ranging cohort is being added in familial adenomatous polyposis (FAP), building on what the article describes as compelling early clinical evidence for zolucatetide in patients with FAP and concomitant desmoid tumors. No cohort size, efficacy figures, or timing details are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Top biotechnology stock pick from Guggenheim
- Needham raises Starling Oncology stock price target on growth outlook
- Stifel raises IQVIA stock price target on improving market backdrop